Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval

Sep 30 2011

• By The Pink Sheet Daily

Related Content

Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?

Aug 29 2011

ROCKET AF’s Design Causes Headaches For <i>Xarelto</i> Sponsors

Sep 19 2011

Bayer/J&J's Xarelto Gets Advisory Cmte. Endorsement In A-Fib, But Not First-Line Use

Sep 08 2011

Xarelto Approval For DVT Bodes Well For Coming Indications

Jul 05 2011

Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS

Jul 25 2011

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window